Mesoblast Limited (AU:MSB) has released an update.
Mesoblast Limited has announced an upcoming filing of their Biologics License Application with the FDA for their lead product Ryoncil, targeting a second-half 2024 approval. The company’s CEO highlighted Phase 3 advancements in heart failure and back pain treatments, and a robust U.S. intellectual property portfolio extending through at least 2041. Mesoblast’s innovative cellular medicines aim to combat severe inflammatory conditions and are backed by a strong global IP presence.
For further insights into AU:MSB stock, check out TipRanks’ Stock Analysis page.
